Increased Nasal Blimp1 + Treg Cells After Sublingual Immunotherapy Reflect the Efficacy of Treatment in Allergic Rhinitis

Overview

Journal Adv Ther

Date 2024 Mar 5

PMID 38443650

Authors

Yue Pan

Xinxin Zhang

Huanting Geng

Yan Yu

Jianyong Liu

Menglin Li

Huijun Yang

Yifang Yuan

Yao Xu

Yujia Wu

Geping Wu

Xingkai Ma

Lei Cheng

Affiliations

Soon will be listed here.

Abstract

Introduction: Allergen-specific immunotherapy (AIT) plays a pivotal role in altering the immune status and tissue responses in allergic rhinitis (AR). This study focuses on the impact of sublingual immunotherapy (SLIT) involving dust mite drops, exploring the modulation of regulatory T cells (Treg) and their specific marker, BLIMP1, in the nasal mucosa.

Methods: Immune cells were isolated from nasal lavage fluid of patients with AR undergoing SLIT (n = 94). Treg cells were analyzed for BLIMP1 expression, and chemokine levels associated with Treg recruitment were assessed using Luminex assay. Patients were categorized on the basis of SLIT efficacy and followed for changes after discontinuation.

Results: SLIT induced a significant increase in nasal Treg cells (7.09 ± 2.59% vs. 0.75 ± 0.27%, P < 0.0001). BLIMP1 expression in Treg cells notably increased after SLIT (0.36 ± 0.22% to 16.86 ± 5.74%, P < 0.0001). Ineffective SLIT cases exhibited lower levels of nasal Treg and Blimp1 + Treg cells (both P < 0.0001). Receiver operating characteristic (ROC) analysis confirmed their potential as efficacy predictors (AUC = 0.908 and 0.968, respectively). SLIT discontinuation led to a significant reduction in Treg and Blimp1 + Treg cells (P < 0.001), emphasizing their maintenance during treatment. Pro-inflammatory cytokines decreased (P < 0.001), while CCL2 associated with Treg recruitment increased (P = 0.0015).

Conclusion: Elevated nasal Blimp1 + Treg cells serve as a predictive biomarker for SLIT responsiveness in pediatric AR. Their influence on immunotherapy effectiveness contributes to a nuanced understanding of SLIT mechanisms, allowing for disease stratification and personalized treatment plans. This study offers scientific support for predicting SLIT efficacy, enhancing the prospects of improved treatment outcomes in AR.

References

Brozek J, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S . Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140(4):950-958. DOI: 10.1016/j.jaci.2017.03.050. View

Alvarez-Cuesta E, Bousquet J, Canonica G, Durham S, Malling H, Valovirta E . Standards for practical allergen-specific immunotherapy. Allergy. 2006; 61 Suppl 82:1-20. DOI: 10.1111/j.1398-9995.2006.01219_1.x. View

Cox L, Linnemann D, Nolte H, Weldon D, Finegold I, Nelson H . Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006; 117(5):1021-35. DOI: 10.1016/j.jaci.2006.02.040. View

Chen B, Long Z, Huang Y, Zeng J . [Efficacy of sublingual immunotherapy with dermatophagoides farinae drops in monosensitized and polysensitized patients with allergic rhinitis]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013; 48(7):549-54. View

Cui L, Li J, Li Y, Xia Z . Long-Term Efficacy of Sublingual Mite Immunotherapy in Monosensitized and Polysensitized Children with Allergic Rhinitis: A 7-Year Prospective Study. Int Arch Allergy Immunol. 2019; 180(2):144-149. DOI: 10.1159/000500524. View

Shao J, Cui Y, Zheng Y, Peng H, Zheng Z, Chen J . Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis. Am J Rhinol Allergy. 2014; 28(2):131-9. DOI: 10.2500/ajra.2014.28.4006. View

Lin X, Lin H, Wei X, Huang Q . The efficacy and safety of sublingual immunotherapy in children and adult patients with allergic rhinitis. Allergol Immunopathol (Madr). 2017; 45(5):457-462. DOI: 10.1016/j.aller.2016.10.016. View

Lin Z, Zhou L, Luo X, Xia W, Chen D, Xu R . Suppression of TIM-1 predicates clinical efficacy of sublingual immunotherapy for allergic rhinitis in children. Int J Pediatr Otorhinolaryngol. 2013; 77(8):1345-9. DOI: 10.1016/j.ijporl.2013.05.032. View

Wang C, Wang K, Liu S, Qin X, Chen K, Zhang T . Decreased level of osteopontin in children with allergic rhinitis during sublingual immunotherapy. Int J Pediatr Otorhinolaryngol. 2016; 81:15-20. DOI: 10.1016/j.ijporl.2015.12.001. View

10.

Ma X, Zhang Y, Gu X, Wu G, Liu J, Lu J . A Retrospective Cohort Study of Sublingual Immunotherapy with Standardized Dermatophagoides farinae Drops for Allergic Rhinitis. Adv Ther. 2021; 38(5):2315-2322. DOI: 10.1007/s12325-021-01686-x. View

11.

Okamoto Y, Fujieda S, Okano M, Yoshida Y, Kakudo S, Masuyama K . House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy. 2016; 72(3):435-443. PMC: 5324568. DOI: 10.1111/all.12996. View

12.

Wang D, Chen L, Cheng L, Li K, Yuan H, Lu J . Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope. 2013; 123(6):1334-40. DOI: 10.1002/lary.23935. View

13.

Shamji M, Sharif H, Layhadi J, Zhu R, Kishore U, Renz H . Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma. J Allergy Clin Immunol. 2022; 149(3):791-801. DOI: 10.1016/j.jaci.2022.01.016. View

14.

Salles G, Chen J, Zhang I, Kerbauy F, Wu J, Wade S . Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. Adv Ther. 2024; 41(5):1938-1952. PMC: 11052850. DOI: 10.1007/s12325-024-02822-z. View

15.

Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R . Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004; 199(11):1567-75. PMC: 2211782. DOI: 10.1084/jem.20032058. View

16.

Jartti T, Burmeister K, Seroogy C, Jennens-Clough M, Tisler C, Salazar L . Association between CD4(+)CD25(high) T cells and atopy in children. J Allergy Clin Immunol. 2007; 120(1):177-83. DOI: 10.1016/j.jaci.2007.03.008. View

17.

Collison L, Workman C, Kuo T, Boyd K, Wang Y, Vignali K . The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007; 450(7169):566-9. DOI: 10.1038/nature06306. View

18.

Shamji M, Durham S . Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy. 2011; 41(9):1235-46. DOI: 10.1111/j.1365-2222.2011.03804.x. View

19.

Lou W, Wang C, Wang Y, Han D, Zhang L . Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type I T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children. Pediatr Allergy Immunol. 2011; 23(2):140-9. DOI: 10.1111/j.1399-3038.2011.01249.x. View

20.

Pilette C, Nouri-Aria K, Jacobson M, Wilcock L, Detry B, Walker S . Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol. 2007; 178(7):4658-66. DOI: 10.4049/jimmunol.178.7.4658. View